Burkitt Lymphoma - Pipeline Review, H2 2016

  • ID: 3960451
  • Drug Pipelines
  • 124 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Arvinas, Inc.
  • bluebird bio, Inc.
  • Boehringer Ingelheim GmbH
  • Immunomedics, Inc.
  • Patrys Limited
  • MORE
Burkitt Lymphoma - Pipeline Review, H2 2016

Burkitt Lymphoma - Pipeline Review, H2 2016, provides an overview of the Burkitt Lymphoma (Oncology) pipeline landscape.

Burkitt lymphoma is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. Symptoms include fever, night sweats, swollen lymph nodes and weight loss. The disease is more common in males and people with compromised immune systems, such as those with HIV/AIDS. Treatment includes chemotherapy and radiation therapy.

Report Highlights:

Burkitt Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkitt Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkitt Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 13 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Burkitt Lymphoma.

Burkitt Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Burkitt Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkitt Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkitt Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkitt Lymphoma (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkitt Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkitt Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Arvinas, Inc.
  • bluebird bio, Inc.
  • Boehringer Ingelheim GmbH
  • Immunomedics, Inc.
  • Patrys Limited
  • MORE
Introduction

Burkitt Lymphoma Overview

Therapeutics Development

Pipeline Products for Burkitt Lymphoma - Overview

Pipeline Products for Burkitt Lymphoma - Comparative Analysis

Burkitt Lymphoma - Therapeutics under Development by Companies

Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes

Burkitt Lymphoma - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Burkitt Lymphoma - Products under Development by Companies

Burkitt Lymphoma - Products under Investigation by Universities/Institutes

Burkitt Lymphoma - Companies Involved in Therapeutics Development

AbbVie Inc

Arvinas, Inc.

bluebird bio, Inc.

Boehringer Ingelheim GmbH

Constellation Pharmaceuticals, Inc.

Immunomedics, Inc.

Karyopharm Therapeutics, Inc.

Millennium Pharmaceuticals Inc

Patrys Limited

Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

Theravectys SA

Burkitt Lymphoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

19-3s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

20-3s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bb-2121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for ALL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD30 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denintuzumab mafodotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E1-3s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixazomib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PATLM-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selinexor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SH-7129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SH-7133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SH-7139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BET for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volasertib trihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkitt Lymphoma - Dormant Projects

List of Tables

Number of Products under Development for Burkitt Lymphoma, H2 2016

Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Burkitt Lymphoma - Pipeline by AbbVie Inc, H2 2016

Burkitt Lymphoma - Pipeline by Arvinas, Inc., H2 2016

Burkitt Lymphoma - Pipeline by bluebird bio, Inc., H2 2016

Burkitt Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016

Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H2 2016

Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016

Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Burkitt Lymphoma - Pipeline by Patrys Limited, H2 2016

Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016

Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Burkitt Lymphoma - Pipeline by Theravectys SA, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Burkitt Lymphoma - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Burkitt Lymphoma, H2 2016

Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AbbVie Inc
- Arvinas, Inc.
- bluebird bio, Inc.
- Boehringer Ingelheim GmbH
- Constellation Pharmaceuticals, Inc.
- Immunomedics, Inc.
- Karyopharm Therapeutics, Inc.
- Millennium Pharmaceuticals Inc
- Patrys Limited
- Seattle Genetics, Inc.
- Takeda Pharmaceutical Company Limited
- Theravectys SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll